Results 31 to 40 of about 23,620 (204)

Nitrofurantoin: Furious against bacteria? An in vitro study to test nitrofurantoin as an intracanal medicament against Enterococcus Faecalis [PDF]

open access: yes, 2022
In vitro evaluation of nitrofurantoin as an intracanal medicament against Enterococcus Faecalis. Materials and Methods: 150 single-rooted premolar teeth were chosen and instrumented using a Protaper gold rotary file system; the root canals of these teeth
Jhamb, Ashu   +9 more
core   +1 more source

Nitrofurantoin-induced interstitial lung disease

open access: yesJournal of Clinical and Scientific Research, 2022
We report the case of a 55-year-old woman diagnosed with interstitial lung disease due to long-term nitrofurantoin therapy that was administered for recurrent urinary tract infection.
Mohammed Salman   +3 more
doaj   +1 more source

Nitrofurantoin-Associated Bronchiolitis Obliterans Organizing Pneumonia: Report of a Case [PDF]

open access: yes, 2008
Bronchiolitis obliterans organizing pneumonia due to nitrofurantoin has rarely been reported and is associated with poor outcomes. A case of nitrofurantoin-associated bronchiolitis obliterans organizing pneumonia responsive to drug withdrawal and ...
Rani Kanthan   +2 more
core   +1 more source

Characterization of Fosfomycin and Nitrofurantoin Resistance Mechanisms in Escherichia coli Isolated in Clinical Urine Samples

open access: yesAntibiotics, 2020
Fosfomycin and nitrofurantoin are antibiotics of choice to orally treat non-complicated urinary tract infections (UTIs) of community origin because they remain active against bacteria resistant to other antibiotics.
Antonio Sorlozano-Puerto   +4 more
doaj   +1 more source

Development of a Physiologically Based Pharmacokinetic Model for Nitrofurantoin in Rabbits, Rats, and Humans

open access: yesPharmaceutics, 2023
Nitrofurantoin (NFT) is a commonly used antibiotic for the treatment of urinary tract infections that can cause liver toxicity. Despite reports of hepatic adverse events associated with NFT exposure, there is still limited understanding of the interplay ...
Raju Prasad Sharma   +2 more
doaj   +1 more source

Acute Lung Toxicity Due to Nitrofurantoin Use: With A Case [PDF]

open access: yes, 2021
5-nitrofuran türevi olan nitrofurantoin, kadın hastalarda komplikasyonsuz idrar yolu infeksiyonlarının tedavisinde ilk seçenektir. Kullanımında önemli yan etkiler bildirilmiştir ve bunlar arasında dozdan bağımsız olarak akciğer tutulumu da mevcuttur ...
Arif İşcan   +5 more
core   +1 more source

High resistance prevalence towards ampicillin, co-trimoxazole and ciprofloxacin, among uropathogenic Escherichia coli isolates in Mexico City

open access: yesJournal of Infection in Developing Countries, 2008
Background : The prevalence of antimicrobial resistance among uropathogenic E. coli varies widely worldwide; to guide empirical therapy is necessary to have local, up-to-date susceptibility data.
Jose Luis Arredondo-García   +1 more
doaj   +1 more source

Risks of long-term use of nitrofurantoin for urinary tract prophylaxis in the older patient

open access: yesUrological Science, 2016
Purpose: To review the current literature on reported pulmonary, liver, and nerve adverse reactions (ARs) of long-term Nitrofurantoin (NF) suppression in older patients treated for urinary tract infections (UTIs).
Lauren L. Rego   +2 more
doaj   +1 more source

Nitrofurantoin Pneumonitis

open access: yes, 1977
A case of acute nitrofurantoin induced pneumonitis is reported. The various pulmonary toxicities of nitrofurantoin are also discussed.
Douglass J. Stennett   +2 more
core   +1 more source

Nitrofurantoin susceptibility profile versus other antibiotics tested in uropathogens- a retrospective study from India

open access: yesMicrobes, Infection and Chemotherapy
Introduction. Urinary Tract Infection (UTI) is one of the most common bacterial infections encountered by clinicians worldwide. The emergence of multidrug-resistant uropathogens necessitates a review of their susceptibility profiles.
Anuja Gupta, Bhawna KUNAL
doaj   +1 more source

Home - About - Disclaimer - Privacy